Screener
Vor Biopharma VOR Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220689
| (in thousands, except share and per share amounts) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $17,595 | $26,701 |
| General and administrative | 17,565 | 6,590 |
| Total operating expenses | $35,160 | $33,291 |
| Loss from operations | (35,160) | (33,291) |
| Other income (expense): | ||
| Interest income | 3,935 | 805 |
| Change in fair value of warrant liabilities | (188,360) | — |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Vor Biopharma's total operating expenses?
- Vor Biopharma (VOR) reported total operating expenses of $35.16M in Q1 2026.
- How has Vor Biopharma's total operating expenses changed year-over-year?
- Vor Biopharma's total operating expenses increased by 5.6% year-over-year, from $33.29M to $35.16M.
- What is the long-term trend for Vor Biopharma's total operating expenses?
- Over 4 years (2021 to 2025), Vor Biopharma's total operating expenses has grown at a 52.3% compound annual growth rate (CAGR), from $69.02M to $371.64M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Vor Biopharma's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude